Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: (CANCER-COG)

Patients: Inclusion Criteria: Benign meningioma (grade I), or atypical meningioma (grade II) Histologic proven of benign meningioma, atypical meningioma or unequivocal radiological diagnosis of skull base meningioma if biopsy is recused. Indication of irradiation validated by a multidisciplinary meeting Age >20 years and <65 years Expected overall survival >10 years Adjuvant or exclusive irradiation is allowed. Signed informed consent form WHO Performance status equal to 0 or 1 Patient affiliated to the French social health insurance Patient whose neuropsychological abilities allow to follow the requirements of the protocol Exclusion Criteria: Patient with mutation in a known predisposition gene (NF-2, SMARCE-1). Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia. Other localization than skull base meningioma Histology/radiological features rather different than grade I-II meningioma Histologic proven grade III meningioma History of epilepsy with antiepileptic drug Contraindication to MRI Patient with a history of brain irradiation. Patient with a history of cancer in the last five years (excluding skin baso-cellular carcinoma) Pregnant/breastfeeding woman Any geographical conditions, social and associated psychopathology that may compromise the patient's ability to participate in the study Participation in a therapeutic trial evaluating a radiotherapy schedule or a new drug or combination for less than 30 days Patient deprived of freedom or under guardianship Hypersensibility to Gadolinium Participants free of brain disease or cancer history: Inclusion Criteria: Subject without any history of neurological disease (cerebral stroke, epilepsy, Intra cranial Neurosurgery procedure, meningioma, pituitary adenoma, Parkinson disease,Dementia…) or absence of personality disorders and progressive psychiatric pathology Age >20 years and <65 years Signed informed consent form WHO Performance status equal to 0 or 1 Subject affiliated to the French social health insurance Subject whose neuropsychological abilities allow to follow the requirements of the protocol No major cognitive disorder that may compromise the realization of cognitive evaluations, defined as a MoCA score in accordance with the threshold depending on age and educational level according to the GRECOGVASC normative data Non-inclusion criteria Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia History of epilepsy with antiepileptic drug Subject with a history of brain irradiation Subject with a history of cancer in the last five years (Excluding skin baso-cellular carcinoma) Pregnant/breastfeeding woman Any geographical conditions, social and associated psychopathology that may compromise the subject's ability to participate in the study Participation in a therapeutic trial - Subject deprived of freedom or under guardianship